ArchivePatients with heart failure (HF) have a higher risk of death, and diabetes mellitus (DM) is an important risk factor for HF. Sodium-glucose linked transporter 2 (SGLT2) inhibitor, as a new anti-hyperglycemia drug in recent years, has been proved to prevent cardiovascular events and improve the prognosis of patients with HF with reduced ejection fraction (HFrEF), and reduce the risk of HF hospitalization and cardiovascular death. This benefit is consistent in patients with or without DM. This article reviewed the previous literature on the effects of SGLT2 inhibitors on cardiovascular outcomes, especially on HF, in order to provide references for clinical medication.
Dyslipidemia, characterized by elevated low density lipoprotein-cholesterol (LDL-C), is an important risk factor for atherosclerotic cardiovascular disease (ASCVD). Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a class of compounds that inhibit PCSK9 and are a class of new lipid-lowering drugs. It interferes with the recycling of low density lipoprotein receptor (LDLR), thus hindering LDL-C clearance mediated by LDLR, which brings new hope for lipid-lowering therapy. This article reviewed the discovery, structure, regulation and biological functions of PCSK9 targets, focusing on the pharmacodynamics, pharmacokinetics and recent clinical research progress of monoclonal antibodies and small interfering RNA drugs, in order to provide reference for clinical diagnosis and treatment.
Sodium-glucose linked transporter 2 (SGLT2) inhibitors are a new class of anti-diabetes mellitus (DM) drugs. SGLT2 is usually involved in the reabsorption of about 90% of the glucose filtered by the glomerular. SGLT2 inhibitors directly reduce blood sugar by inhibiting the active transport of glucose by SGLT2, inhibiting the reabsorption of glucose by the kidneys, increasing urinary glucose excretion. SGLT2 inhibitors are becoming increasingly important in the treatment of type 2 DM (T2DM), as they can not only reduce blood glucose, but also have cardio-renal protective effects. SGLT2 inhibitors have been widely used after being marketed in China. Now, the pharmacokinetic characteristics, hypoglycemic effect, cardiovascular protection, renal protection and adverse reactions of SGLT2 inhibitors that have been listed in China were compared in order to provide reference for clinical medication.
Pharmacoeconomic evaluation is an important tool for drug access and pricing decisions. The results of pharmacoeconomic evaluation carried out under different perspectives are different due to different costs and health outcomes they cover. However, the research perspective that should be adopted for the pharmacoeconomic evaluation to support the adjustment decision of the national reimbursement drug list in China (except Hong Kong, Macao and Taiwan) has not been clearly defined. Based on the submission guidelines of typical countries and regions, this paper analyzed the characteristics and applicable scenarios of different perspectives, and suggested that in China (except Hong Kong, Macao and Taiwan), started from the positioning of basic medical insurance system, the baseline analysis should be conducted from the perspective of basic medical insurance payers, and supplementary analysis should be conducted from other appropriate perspectives. Besides, the costs and health outcomes that should be included in the assessment under the corresponding perspective need to be specified in the submission guidelines.
Utility measurement is one of the important indicators reflecting health outcomes in pharmacoeconomic evaluation, and it has a large impact on the results of pharmacoeconomic evaluation. This paper analyzed and discussed several considerations of utility measurement defined in guidelines for pharmacoeconomic evidence submission in typical countries (regions), from the six aspects of utility indicators, target populations for utility measurement, utility measurement tools, types of multi-attribute utility instruments, utility value sets and sources of utility data. It was suggested that quality adjusted life years should be used as the utility index in the cost-utility analysis for adjustments of Chinese (except Hong Kong, Macao and Taiwan) medical insurance drug list, and the indirect methods should be used to measure the utility weights for general populations. In addition, the priority of different data sources of utility weights should be clarified.
Pharmacoeconomic evaluation is an important reference evidence for the adjustment and decision-making of national reimbursement drug list in each country or region. The value of the discount rate can heavily affect the pharmacoeconomic evaluation results, so it needs to be further standardized. Based on the submission guidelines of typical countries and regions, this paper analyzed the connotation and characteristics of the discount rate and explored the theoretical basis and calculation method, so as to provide reference for the development of discount rate of pharmacoeconomic evaluation to support the adjustment of reimbursement drug list in China (except Hong Kong, Macao and Taiwan).
Time horizon has a direct impact on the "incremental cost-effectiveness ratio" of pharmacoeconomic evaluation results. There are no clear requirements or explanations on the setting method of time horizon in the guidance documents related to pharmacoeconomic evaluation, such as national health policies and pharmacoeconomic evaluation guidelines. Based on the official specifications of typical countries and regions, the paper analyzed the characteristics and descriptions of different official specifications on time horizon. It was suggested that China (except Hong Kong, Macao and Taiwan) should pay attention to the detailed explanation of the determinants of the selection of time horizon and the rationality of the selection results when conducting pharmacoeconomic evaluation based on official specifications, and present the uncertainty analysis of time horizon and the corresponding results in the submission guidelines.
To explore the effects and molecular mechanism of repaglinide on podocyte injury induced by high glucose.
Podocytes from conditionally immortal mice were divided into control group (5.5 mmol/L glucose), high glucose group (30 mmol/L glucose), experimental group 1 (30 mmol/L glucose+0.25 μmoL/L repaglinide), experimental group 2 (30 mmol/L glucose+0.50 μmoL/L repaglinide) and experimental group 3 (30 mmol/L glucose+1.00 μmoL/L repaglinide). Cell viability and apoptosis were detected by cell counting kit and flow cytometry. The levels of malondialdehyde (MDA) and transforming growth factor β1 (TGF-β1) in cells were detected by the kit. Real-time fluorescence PCR and western blot were used to detect the expression of sodium-glucose linked transporter 2 (SGLT2). SGLT2 overexpression plasmid was transfected into podocyte cells, and the changes of the above indicators were detected after intervention with high glucose and repaglinide.
Compared with the control group, podocyte survival rate and expression of Ki67 protein in the high glucose group were decreased, apoptosis rate, MDA, TGF-β1 levels and expression of SGLT2 were increased (P<0.05). Compared with the high glucose group and experimental group 1, podocyte survival rate and expression of Ki67 protein in the experimental group 2 and 3 were increased, and the apoptosis rate, MDA, TGF-β1 levels and expression of SGLT2 were decreased (P<0.05). Compared with the experimental group 2, the podocyte survival rate and expression of Ki67 protein in the experimental group 3 were increased, and the apoptosis rate, MDA, TGF-β1 levels and expression of SGLT2 were decreased (P<0.05). Overexpressing SGLT2 partially reversed the protective effects of repaglinide on podocyte injury induced by high glucose (P<0.05).
Repaglinide has a protective effect on podocyte injury induced by high glucose, which may be related to down-regulation of expression of SGLT2.
To investigate the effects and mechanism of baicalin on pulmonary function in bronchiectasis rats based on interleukin (IL)-23/IL-17 axis.
A total of 65 SD rats were selected, 10 of which were used as the control group without any intervention, and the rest rats were injected with Pseudomonas aeruginosa to construct the bronchiectasis rat model. Five rats were used to confirm the modeling results. The remaining 50 rats were randomly divided into model group, low-dose (50 mg/kg), medium-dose (100 mg/kg), high-dose (200 mg/kg) baicalin group and positive control (levofloxacin, 96.7 mg/kg) group, with 10 rats in each group. After 14 days of intervention, pulmonary function indexes of rats in each group were measured. The levels of IL-23 and IL-17 in serum and the contents of matrix metalloproteinase (MMP)9 and tissue inhibitor of metalloproteinase (TIMP)-1 in lung tissue were detected by enzyme linked immunosorbent assay (ELISA). Hematoxylin and eosin (HE) staining was used to observe the pathological changes of lung tissue in each group. Western blot (WB) was used to detect the protein expression levels of IL-23 and IL-17 in the lung tissue of rats in each group.
Compared with the model group, the inflammatory cell infiltration, bronchiectasis, alveolar structure damage in the lung tissue of rats in the low-dose, medium-dose and high-dose baicalin groups were relieved to varying degrees, the lung function index and TIMP-1 content were increased (P<0.01), and the levels of MMP-9, IL-23, IL-17 and the expression of IL-23, IL-17 protein were decreased (P<0.01). There were no significant differences in the indexes between the high-dose baicalin group and the positive control group (P>0.05).
Baicalin may reduce the inflammatory level and lung tissue injury in bronchiectasis rats and improve lung function by inhibiting the IL-23/IL-17 axis.
To study the clinical effects of Qizhen granules on patients with type 2 diabetes mellitus (T2DM) of Qi deficiency type and abdominal obesity with concept of "treating different diseases with same method".
A total of 60 patients with T2DM of Qi deficiency type and 60 patients with abdominal obesity were included in the inpatient and outpatient departments of endocrinology, Yueyang hospital of integrated traditional Chinese and western medicine, Shanghai university of traditional Chinese medicine (TCM) from January 2018 to December 2019. The two types of patients were randomly divided into observation group and control group, with 30 cases in each group. On the basis of diet, exercise therapy and maintaining the original hypoglycemic regimen in T2DM group, Qizhen granules and control drug were added to the observation group and control group respectively. On the basis of diet and exercise therapy, the observation group and the control group were treated with Qizhen granules and control drug respectively. The course of treatment was 12 weeks. The indexes of saccharometabolism in T2DM group and the physique in abdominal obesity group were observed before and after treatment. The homeostasis model assessment of insulin resistance (HOMA-IR) was compared between the two groups of patients.
After treatment, fasting blood glucose, 2-hour postprandial blood glucose and glycosylated hemoglobin in the T2DM observation group were significantly lower than those in the T2DM control group (P<0.01). And the observation group was better than the control group, the difference was statistically significant (P<0.05). The body mass index, waist circumference and waist hip of the abdominal obesity observation group were significantly improved compared with those before treatment (P<0.01), and the observation group was better than the control group (P<0.01). HOMA-IR in the two groups decreased significantly (P<0.01), And the observation group was better than the control group, the difference was statistically significant (P<0.05). The curative effect of TCM syndromes in the observation group was better than that in the corresponding control group, and the difference was statistically significant (P<0.01).
Qizhen granules can treat different diseases at the same time for patients with T2DM of syndrome of Qi deficiency and abdominal obesity with concept of "treating different diseases with same method", and it may improve IR and symptoms by supplementing Qi.
To investigate the effects of diterpene ginkgolides meglumine on blood homocysteine (Hcy), angiotensin-Ⅱ (Ang-Ⅱ) and neurological function in acute cerebral infarction (CI) patients with CYP2C19 mutation.
A total of 82 acute CI patients with CYP2C19 mutation who were treated in Dalian No.3 people's hospital from January 2018 to April 2020 were selected and divided into the control group (n=41) and the observation group (n=41), using the random number table method. The control group was given aspirin and clopidogrel, and the drug dose was increased. And the observation group was additionally given diterpene ginkgolides meglumine. The platelet function, hemorheology, Hcy, Ang-Ⅱ and nerve function were compared between the two groups before and after treatment.
Before treatment, there were no significant differences in CD62p, CD63 and platelet aggregation rate, hemorheology related, Hcy and Ang-Ⅱ levels, and neurological function-related indexes between the two groups (P>0.05). After treatment, the levels of CD62p, CD63, platelet aggregation rate, hemorheology-related indexes, Hcy and Ang-Ⅱ levels in the observation group were significantly lower than those in the control group (P<0.05), while the levels of brain-derived neurotrophic factor in the observation group were significantly higher than those in the control group (P<0.05). There were statistically significant differences in the above indexes between the observation group and the control group before and after treatment (P<0.05). After treatment, the neuron-specific enolase level and the National Institutes of Health Stroke Scale score were significantly lower than those in the control group (P<0.05), and there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).
Diterpene ginkgolides meglumine can effectively improve platelet function and hemorheological indexes, down regulate the levels of Hcy and Ang-Ⅱ, relieve the symptoms of neurological deficit and improve neurological function in acute CI patients with CYP2C19 mutation.
To observe and analyze the clinical effects of Jianpi Xiaoying decoction on thyroid peroxidase autoantibody (TPOAb), thyroglobulin antibody (TGAb), estradiol (E2), prolactin (PRL) and progestogen (P) in women of childbearing age with Hashimoto thyroiditis (HT).
Women of childbearing age with HT diagnosed in the outpatient and inpatient department of endocrinology, LongHua hospital Shanghai university of traditional chinese medicine from October 2019 to December 2020 were randomly divided into observation group (n=32, Jianpi Xiaoying decoction) and control group (n=31, selenium yeast). The course of treatment was 12 weeks. The improvement of symptoms, signs and laboratory indexes were observed before and after treatment.
The levels of TPOAb and TGAb in the two groups were lower than those before treatment (P<0.01), and the observation group was better than the control group (P<0.05). The levels of E2 and P in the observation group were significantly higher than those before treatment (P<0.01), and the observation group was better than the control group (P<0.01). The PRL in both groups was lower than before treatment (P<0.01), and the observation group was better than that of the control group (P<0.01). The clinical symptoms and signs of the two groups were significantly improved compared with those before treatment (P<0.01), and the observation group was better than the control group (P<0.01). The curative effects of the control group was significantly better than those of the control group, the difference was statistically significant (P<0.01).
Jianpi Xiaoying decoction can significantly reduce the titers of autoantibodies TPOAb and TGAb in women of childbearing age with HT, improve the clinical symptoms and signs, and regulate the level of sex hormones in patients with better safety.
To observe effects of azithromycin combined with interferon-α(IFN-α) on mycoplasma pneumoniae pneumonia (MPP).
A total of 170 children with MPP diagnosed in Tongling maternal and child health hospital from November 2018 to August 2019 were selected. They were randomly divided into control group and observation group. The control group was given azithromycin and the observation group was given azithromycin combined with IFN-α. The curative effect and the changes of granulocyte-macrophage colony stimulating factor (GM-CSF) and serum amyloid A (SAA) were observed before and after treatment. The airway reactivity was observed by hypertonic saline bronchial provocation test.
After treatment, GM-CSF of the observation group was lower than that of control group (P<0.05). Forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), peak expiratory flow (PEF) and maximum mid expiratory flow (MMEF) decreased. The △FVC of the observation group was (5.07±4.32), lower than that of the control group (7.24±5.92), the △MMEF (12.17±7.33) was lower than that of the control group (16.23±8.81) (P<0.05). The total effective rate of observation group (88.23%) was higher than that of control group (69.41%)(P<0.05).
Compared with azithromycin, azithromycin combined with IFN-α can achieve better curative effect and reduce airway responsiveness in children with MPP.
To investigate the effect of conversion of efavirenz (EFV) to rilpivirine (RPV) on blood lipids in adult human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) patients.
The clinical data of 67 patients with HIV/AIDS who were converted from EFV to RPV in Beijing Youan hospital, capital medical university, from March 2019 to September 2021 were retrospectively analyzed. The HIV viral load, CD4 cell count, blood lipid, liver and kidney function before and after RPV conversion were compared.
After the conversion, the levels of triglycerides (TG), total cholesterol (TC) and high density lipoprotein-cholesterol (HDL-C) decreased, and the differences were statistically significant (P<0.05). The level of low density lipoprotein-cholesterol (LDL-C) decreased, but the difference was not statistically significant (P>0.05). After the conversion, the total abnormal rate of total blood lipid was increased, and the abnormal rates of TC and LDL-C decreased, but the differences were not statistically significant (P>0.05). The abnormal rate of TG decreased from 52.24% to 32.84%, and the abnormal rate of HDL-C increased from 31.34% to 68.66%, the differences were statistically significant (P<0.05). The absence of tenofovir in regimens was a risk factor for elevated LDL-C. After conversion, the levels of alanine aminotransferase, glutamine aminotransferase and creatinine decreased, and the differences were statistically significant (P<0.05).
RPV can significantly reduce TG and TC, but also reduce the level of HDL-C. Its benefit in blood lipid still needs more research.
To evaluate the cost-effectiveness of osimertinib for adjuvant treatment of patients with epidermal grouth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) after tumor resection from the perspective of Chinese healthcare system.
A 5-state Markov model with 1-month cycle was constructed, and the lifetime horizon was used. Data on patient baseline characteristics, transition probabilities, incidence of adverse events and health utilities were mainly derived from ADAURA study, supplemented by CancerLinQ database, FLAURA study and published literatures. Medical costs were derived from Chinese government documents, literature, and clinical expert surveys. Scenario analysis, one-way sensitivity analysis and probabilistic sensitivity analysis were conducted simultaneously.
Base-case analysis results showed that for patients with EGFR mutation-positive NSCLC after tumor resection, the incremental cost of osimertinib compared with placebo was 25 395.25 yuan, the incremental quality adjusted life year (QALY) was 3.25, the incremental cost-effectiveness ratio (ICER) was 7 812.45 yuan/QALY, which was much lower than 1 times Chinese per capita GDP (72 447.00 yuan in 2020). Osimertinib has cost-effectiveness. Scenario analysis, one-way sensitivity analysis and probabilistic sensitivity analysis indicated that base-case analysis results were robust.
Under the threshold of 1-time Chinese per capita GDP, osimertinib was predicted to be the cost-effective treatment option compared with placebo for patients with EGFR mutation-positive NSCLC after tumor resection in China.
To explore the feasibility of different point urinary sodium formula to evaluate 24-hour urinary sodium excretion.
A total of 226 inpatients in the department of hypertension, northern area of Ruijin hospital from May to December 2016 were analyzed retrospectively. Point urine and 24-hour urinary sodium excretion was estimated by three point urine sodium formulas, Sun C method, Kawasaki method and Tanaka method. The differences between 24h urinary sodium estimated value and measured value were compared by paired rank sum test. The consistency of 24-hour urinary sodium estimated value and measured value was evaluated by Bland-Altman method.
There were significant differences between the estimated 24-hour urinary sodium [Sun C method 137.4 (111.0, 161.8) mmol/d, Kawasaki method 170.7 (120.0, 217.0)mmol/d, Tanaka method 136.9 (105.4, 166.4)mmol/d] and the actual measured value [142.7 (103.8, 183.5) mmol/d](P<0.05). In male patients, the difference between 24-hour urinary sodium estimated by Sun C method and the actual measured value was the smallest, and there was no significant difference between them (P>0.05). In female patients, there was no significant difference between the estimated 24-hour urinary sodium by Kawasaki method and Tanaka method compared to the actual measured value (P>0.05), while there was significant difference between 24-hour urinary sodium estimated by Sun C method and the actual measured value (P<0.05).
The hospitalized patients with hypertension in our hospital, the reliability of 24-hour urinary sodium estimated by the three formulas is not high. After grouping according to gender, Sun C method has higher significance estimation of hospitalized male patients than female patients.
To observe the predictive effect of osteoporosis self-assessment tool for Asians (OSTA) on osteoporosis (OP) in peritoneal dialysis (PD) patients.
A total of 145 PD patients who underwent bone mineral density (BMD) testing were selected from department of nephrology, Ruijin hospital affiliated to Shanghai Jiao Tong university school of medicine from January 2013 to January 2014. Dual energy X-ray absorptiometry was used to evaluate the incidence of OP in PD patients. PD patients were divided into low-risk group (n=98), medium-risk group (n=33) and high-risk group (n=14) by OSTA index. The BMD levels of the three groups were compared to evaluate the clinical value of OSTA. The levels of serum calcium, phosphorus and parathyroid hormone (PTH) were compared between OP patients and non OP patients, and the independent risk factors of OP were analyzed.
The incidence of OP in female lumbar spine and hip were 14.81% and 11.11%, respectively, and the osteopenia were 25.93% and 48.15%. The incidence of OP in male lumbar spine and hip was 2.44% and 2.38%, and the osteopenia were 26.83% and 20.24%. The detection rates of OP in patients over 65 years old in lumbar and hip were 11.11% and 13.33%, respectively, and the osteopenia were 33.33% and 40.00%. The detection rates of OP in patients under 65 years old in lumbar and hip were 6.00% and 2.00%, respectively, and the osteopenia were by 22.00% and 29.00%. Female and elevated PTH are independent risk factors for OP. According to OSTA index grouping, the detection rates of OP in the lumbar and hip joint in the low-risk group were 5.10% and 1.02%, 12.12% and 12.12% in the medium-risk group, 14.29% and 21.43% in the high-risk group.
The incidence of OP and osteopenia in PD patients was higher, especially in female and the elderly. Poor control of PTH and the female were independent risk factors for OP. The screening effect of OP in PD patients by OSTA index is not effective, which needs to be further improved and verified in clinical application.
To study the predictive value of reduced flow-mediated dilatation (FMD) by brachial artery flow in the occurrence of coronary atherosclerotic heart disease (CHD).
A total of 200 patients who underwent coronary angiography in Shanghai Xuhui district central hospital from January to December 2019 were selected. According to the results of coronary angiography, 154 patients with CHD were divided to the CHD group which included a single vessel, two-vessel and three-vessel group. And the other 46 people without CHD were selected as the control group. Age, hypertension, smoking history and diabetes history were collected. The level of FMD, peripheral venous blood, blood pressure (systolic blood pressure, diastolic blood pressure) were gathered in all patients. Statistical method was used to compare the FMD in the two groups of patients, and the relationship between FMD and CHD was analyzed.
The level of FMD in CHD group was markedly lower than that in control group. The logistic regression analysis showed that decreased FMD was an independent risk factor for CHD, and FMD decreased with the increasing number of diseased coronary branches. Correlation analysis showed that in CHD patients FMD was negatively correlated with CHD risk factors, and positively correlated with high-density lipoprotein.
The level of FMD was negatively with the severity of coronary atherosclerosis, and the decrease of FMD was an independent risk factor for CHD. Reduced FMD can predict the occurrence of coronary heart disease.
To investigate effects of maternal triglyceride (TG) levels on large for gestational age infants (LGA) in the second trimester of pregnancy (24-28 weeks).
A total of 9 096 pregnant women with non-gestational diabetes mellitus who delivered a single live fetus in the maternal and child health hospital, Songjiang district from January 2018 to January 2019 were enrolled. Fasting plasma TG levels were measured during 24-28 weeks of pregnancy. According to the birth weight, they were divided into LGA group (n=1 068) and non-LGA group (n=8 028). Chi-square test and multivariate logistic regression analysis were used to analyze the effects of TG on LGA.
There were significant differences in maternal age, pre-pregnancy body mass index, parity, fetal sex and TG levels between LGA group and non-LGA group (P<0.05). Chi-square test showed that overweight and obesity before pregnancy, postpartum, neonatal male and maternal high TG levels increased the risk of LGA (P<0.05). The results of multivariate logistic regression analysis showed that after controlling the influence of other factors, the high TG level (TG≥2.67 mmol/L) increased the risk of LGA, which was statistically significant (odds ratio=1.36, 95% confidence interval: 1.13-1.64).
High maternal TG levels in the second trimester of pregnancy will increase the risk of LGA. Strengthening supervision of pregnant women with high TG levels in the second trimester of pregnancy may help to reduce the incidence of LGA.
To evaluate the efficacy and safety of heat-clearing and diuresis-promoting and detoxifying in the treatment of psoriasis with damp-heat syndrome by meta analysis.
China National Knowledge Infrastructure, Wanfang, Chongqing VIP, China Biomedical Literature Database, PubMed, Cochrane Library, Embase and other databases were searched to collect randomized controlled trials of heat-clearing and diuresis-promoting and detoxifying in the treatment of psoriasis with damp-heat syndrome from the establishment of the database to December 2020. Two researchers assessed the risk of bias and quality of selected literature according to the Cochrane5.1 manual. State/SE15.1 software was used for meta analysis.
Finally, 13 studies involving 953 patients with psoriasis were included. The results of meta analysis showed that compared with the control group, the total effective rate [odds ratio (OR)=3.03, 95% confidence interval (CI): 2.04-4.48, P<0.000 1)], psoriasis area and severity index (PASI) score (standardized mean difference=-0.68, 95% CI: -0.97--0.39, P<0.000 1) and adverse reactions of the treatment group (OR=0.32, 95%CI: 0.17-0.60, P<0.000 1) were better than those of the control group.
The method of efficacy and safety of heat-clearing and diuresis-promoting and detoxifying in the treatment of psoriasis with damp-heat syndrome can reduce the PASI score and improve the skin lesions, with definite curative effect and high safety.
Homozygous familial hypercholesterolaemia (HoFH) is a severe and rare hypercholesterolemia, which is characterized by a significant increase in low density lipoprotein-cholesterol (LDL-C) and premature atherosclerotic cardiovascular disease. At present, evinacumab, mipomersen, lomitapid and proprotein convertase subtilisin/kexin type 9 inhibitors have been approved for the treatment of HoFH, which effectively solves the problem of the lack of drugs for rare diseases. The article briefly reviewed the clinical research progress on drugs for the treatment of HoFH.
National Medical Products Administration approved the import of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA) in April 2021. As a long-acting GLP-1RA, this product has demonstrated its efficacy and safety through pharmacokinetic studies, SUSTAIN studies and SURE studies before listing. Levels of blood glucose and glycosylated hemoglobin can be reduced with lower incidence of hypoglycemia, lower body weight and lower risk of cardiovascular disease. This article summarized the main clinical research data of semaglutide and relative mechanisms in the treatment of type 2 diabetes mellitus, providing reference for clinical use of semaglutide.
Sleep deprivation (SD) causes significant impairment of attentional capacity in humans. The evaluation of SD impairment of attention and its intervention drugs and measures often requires pilot studies of SD and the use of attention testing tools to evaluate the effect of different SD conditions on a person's attention. It is necessary to comprehensively consider the advantages and disadvantages of different methods and select appropriate attention testing tools. This article reviewed the literature on the effects of SD on attention in recent years, summarized and classified the relevant attention testing tools, analyzed the characteristics of different instruments in drug trials of SD interventions, and to provide ideas for the selection of test methods in the evaluation of attention tests.
To optimize the management of subject visits in clinical trials of drugs for chronic liver disease, meet the requirements of epidemic prevention and control, and reduce the risk of infection during the epidemic of corona virus disease 2019 (COVID-19).
A total of 103 subjects with chronic liver disease who underwent drug clinical trials in department of infectious disease, the second affiliated hospital of Xi'an Jiaotong university were enrolled from 5 December 2019 to 6 December 2020. Clinical data including gender, age, education level, clinical drug research experience, completion of visit and adverse reactions were analyzed, and the coping strategies of liver disease subjects at this stage were put forward according to the possible influencing factors.
During the epidemic of COVID-19, 1 329 subjects were planned to visit, 1 329 subjects were completed (100%), and 1 318 subjects were returned to the hospital (99.17%). Among them, 2 subjects were visited by out of time visits (0.15%). Eleven subjects were allowed to visit hospitals near their place of residence (0.83%). A total of 47 subjects had adverse reactions (3.54%), and no one infected with COVID-19.
During the prevention and control of the COVID-19 epidemic, classified visit management should be implemented according to the visit plan of drug clinical trials to strengthen the communication and coordination between researchers and subjects, protect the rights and interests of subjects, reduce the risk of COVID-19 infection, and ensure the smooth implementation of the research projects.
In order to effectively improve the detection rate of irrational medical orders, comprehensively and individually ensure clinical rational drug use and promote the safety of inpatients' medication use, the pre-audit system--medical intelligent and decision system (MINDs) of routine inpatient medical orders, was refined and revised and supplemented. This article discussed the effect of refined setting of pre-audit system rules on rational use of drug and average drug cost per hospitalization after the selection and dosage of perioperative prevention surgery with antibacterial drug, the selection of special class of antimicrobial agents, the usage and dosage of drugs under different indications, the selection of drugs for patients with renal insufficiency, drug interaction, blood drug concentration monitoring warning and discharge medication from hospital.